/
Psychiatry
Depressive Disorder
73
Pipeline Programs↗
178
Active Trials↗
90
Companies Involved↗
Depressive Disorder is a moderately active landscape with 73 programs across 90 companies. The most active players are Nanjing Chia-tai Tianqing Pharmaceutical, Otsuka. 19 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical40
Phase 212
Phase 319
Approved
No programs
Analysis
Modality Breakdown
97%
Small molecule
67 of 69 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 69 classified programs, each share of the total. Modality classified for 95% of 73 pipeline programs.
Analysis
Trial Status
783
clinical trials
Completed479 · 61%
Recruiting95 · 12%
Terminated54 · 7%
Not yet recruiting49 · 6%
Unknown status45 · 6%
Active, not recruiting26 · 3%
Other35 · 4%
Clinical Trials
Trial Activity
783 trials
Role of Aerobic Exercise as an Adjunct Therapy in the Treatment of Depression in South Punjab, Pakistan
Recruiting·—·Preclinical·NCT07819448·66 enrolled
Examining the Effects of Escitalopram and Memantine on Pattern Separation in Major Depressive Disorder
Recruiting·—·Phase 1·NCT07139834·30 enrolled
Page 1 of 53
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)